



The 3rd edition of the HealthTech Innovation Days (HTID®) gathered major players of the health innovation ecosystem and showcased investment opportunities in Europe.

HTID® has received renewed support from representatives of French and European institutions, as evidenced by the participation of Mr. Emmanuel Macron, President of the French Republic (by video), Mr. Thierry Breton, European Commissioner for the Internal Market, Mrs. Agnès Pannier-Runacher, French Minister Delegate for Industry, Mr. Olivier Véran, Minister of Health.

Paris, France, 11 October 2021: Initiated in 2019 by Maryvonne Hiance, President of HealthTech For Care, The 3rd edition of the HTID, co-organised by HealthTech For Care and EIT Health, brought together major players of the health innovation ecosystem in Europe, with the objective of encouraging new industrial partnerships and investments in order to accelerate healthcare innovation for all patients. **1300** face-to-face and virtual meetings (networking & meetings between all the players in the ecosystem) were organised this year, reflecting the growing interest in this event. HTID brought together **155** European healthtech companies, **15** pharmaceutical and industrial companies and over **300** international investors.

This year, HTID is strengthening its European positioning thanks to **10** new collaborations with European clusters, unconditional support from our **21** sponsors, but also thanks to the mobilisation of HealthTech For Care members and the co-organisation with EIT Health.

HealthTech ecosystem: towards further investment in Europe.

During the inauguration of the HTIDs, Mr Emmanuel Macron, President of the French Republic, reaffirmed the main priorities of the French health innovation strategy and the government's commitment to making France the most dynamic and attractive country in the field of health innovation.

Emmanuel Macron speech: <https://www.youtube.com/watch?v=PH6AHv1DP28>

Also, at the European level, ambitious policies are being developed to promote innovation in Europe. To strengthen cooperation between the various players in the financing industry, Mr Emmanuel Macron, President of the French Republic, brought together some forty international investors (United States, Asia, Europe) at the Elysée Palace for a lunch co-organised with Sofinnova Partners and Maryvonne Hiance on the occasion of the HTID.

Alain Godard, CEO of the European Investment Fund and Jean-Marc Bourez, Managing Director of EIT Health Services & Investment announced the names of the first 8 investors selected for [the Venture Centre of Excellence \(VCoE\)](#), a European co-investment programme with an investment capacity of 1.7 billion, aimed at financing innovation in health.

Guest of honour at the HealthTech Innovation Days, Thierry Breton, European Commissioner for the Internal Market, welcomed the announcement and stressed that "For the health industry ecosystem to become more resilient, we must continue to support its capacity for innovation. The HTIDs are therefore a great opportunity to bring the whole ecosystem together to accelerate innovation in Europe. Today, I am delighted that [the Venture Centre of Excellence programme, supported by the European Commission,](#)

[has brought together venture capital funds with €1.7 billion](#) of investment capacity in life sciences. This will help European life sciences SMEs to bring their ground-breaking innovations to light.”

Speech Thierry Breton: <https://www.youtube.com/watch?v=2RA-j-0Aimk&t=524s>

HTID: A platform for exchange and reflection around 87 international experts who led 20 round tables on the various challenges and actions underway for healthtech: <https://htfc-eu.com/replay-htid3/>

The conferences proposed during these two days of exchange and reflection have allowed to take stock of:

- Tomorrow's economic and investment challenges for the health sector in Europe
- Tomorrow's technological challenges for healthtech companies: access to the market, development of health data, identification, and proposals for the adoption of a value chain for bioproduction and manufacturing at European level.

During this 3rd edition, **the European Council of BioRegions (CEBR) and EIT Health, with the support of EIT Manufacturing**, jointly unveiled a panorama of biomanufacturing ecosystems in Europe, the "**BioManufacturing Landscaping**" as specified by Jérôme Fabiano, Director of External Affairs, EIT Health France. *"The three main findings of this panorama put into perspective the urgent need to train the necessary talents or to promote retraining to meet the needs of this sector of activity for the next few years; to create private and public funding mechanisms within the EU and to strengthen the synergies between them; and to connect the regional ecosystems of excellence in the field."*

- Tomorrow's public health therapeutic challenges: infectious diseases, antibiotic resistance, cancer.

Christian Pierret, former Minister Delegate for Industry, said: *"Faced with health and therapeutic issues, the mobilisation of institutions is commensurate with the challenges they represent for our societies. The European Commission has unveiled its [plan to fight cancer](#). This plan provides for the commitment of €4 billion to fund prevention, research and treatment deployment programmes in the European Union.*

The forum is actively supported by sponsors, including leading pharmaceutical companies: [Amgen](#), [Bristol Myers Squibb](#), [Ipsen](#), [Microsoft](#), [Sanofi](#), [Servier](#), influential healthtech players such as [Alpha Blue Ocean](#), [BNP Paribas](#), [Dechert](#), [Financière Arbevel](#), [Icosa](#), [Invest Securities](#), [Jeito Capital](#), [Life Sciences Acceleration Alliance](#) (LSAA), [McDermott Will & Emery](#), [Rothschild&Co](#), [Sofinnova Partners](#), [Thermo Fisher Scientific](#) as well as institutional partners such as [Bpifrance](#), [Euronext](#) and [Le Leem](#) (Les Entreprises du Médicament)

About HealthTech For Care

The HealthTech For Care endowment fund, chaired by Maryvonne Hiance and created by France Biotech, is designed to support and promote access to healthcare for all and, more specifically, to new medical technologies and new medicines. The missions of the endowment fund are organised around three main areas: to support the development of the entire healthcare ecosystem, to accelerate the development of innovative therapies and medicines, and to promote better access for patients to the healthcare system in France and Europe. The governance of HealthTech For Care includes Maryvonne Hiance, Elsy Boglioli, David Caumartin, Pierre Courteille, Eric Falcand, Marc Le Bozec, Cédric Moreau, Franck Mouthon, Christian Pierret and Christian Policard. HealthTech For Care is supported by its founder *France Biotech* and the network of French health cluster: **Atlanpole biotherapies**, **BioValley France**, **EuroBioMed**, **LyonBioPole**, **Medicen et le clubster NSL**. The endowment fund is also supported by many European players: **Asebio**, **Bio Deutschland**, **BioWin**, **CEBR**,

Federchimica Assobiotec, Flanders.bio, Ireffi, LifeSci, P-Bio, SwendenBio and SwissBiotech and French: ***La French Tech, MabDesign et BusinessFrance.***

About EIT Health

Europe faces a turning point in health. An ageing population, the rising burden of chronic disease, and rowing multi-morbidity are all placing pressure on health systems across Europe.

EIT Health is a vast, vibrant community of world leading health innovators backed by the European Union. Working across borders, our network connects approximately 150 world-class partner organisations, as well as entrepreneurs, start-ups and SMEs from the worlds of business, research, education and healthcare delivery. Our aim is to answer the biggest health challenges Europe faces and we believe that life changing innovation happens when these worlds meet and collaborate. That's why we call this the 'knowledge triangle'.

From our headquarters in Munich, six regional Innovation Hubs and InnoStars cluster, which brings together organisations from regions in which the overall pace of innovation is more moderate, we provide an ecosystem in which fresh thinking can thrive. Our Regional Innovation Scheme further expands our presence in 13 countries across Central, Eastern and Southern Europe. EIT Health also leads the development of the EIT Hub in Israel, which connects innovators across Europe to other key thriving ecosystems beyond the EU. EIT Health is supported by the European Institute of Innovation and Technology (EIT), a body of the European Union. Our ambition is to enable people in Europe to live longer, healthier lives by transforming businesses and delivering new products and services that can progress healthcare in Europe and strengthen our economy.

EIT Health: Together for healthy lives in Europe.

For more information visit: www.eithealth.eu

About HealthTech Innovation Days

The HTID[®] event provides a platform for promising European life sciences companies to accelerate their growth and bring innovation to patients. The 3rd edition took place on October 4&5 2021 on a hybrid format, combining in-person presentations, panels and one-on-one meetings in Paris with a seamless virtual platform for those unable to travel. It is organized by HealthTech For Care and EIT Health. The HealthTech Innovation Days are sponsored by international pharmaceutical companies, other corporates, investors, and many international thought leaders. The fourth edition will take place in 2022. <https://htfc-eu.com/htid/>

About France Biotech, Founder of HealthTech For Care

Founded in 1997, France Biotech is an independent association that brings together HealthTech entrepreneurs and their expert partners. It actively contributes to meet the many challenges of the HealthTech industry (i.e. companies' financing, innovation-related taxes, regulatory and market access related issues) and offers concrete competition and solutions through its commissions and working groups. The goal is to help startups and SMEs become international leaders capable of rapidly developing and bringing innovative solutions to patients. <http://www.france-biotech.fr/>

About LifeSci Advisors

LifeSci Advisors are the global leading investor relations firm within Life Sciences. We combine deep domain life sciences expertise with decades of experience in capital markets to deliver services designed to increase our clients' visibility within the investment community. For more information visit: <https://www.lifesciadvisors.com>

About La French Tech

La French Tech is the nickname of the French ecosystem of startups and all those who make it up, from biosciences to marketplaces, wherever they are in the world. It is also a public organisation at the Ministry of the Economy and Finance - the French Tech mission - founded in 2013 to strengthen this ecosystem with the support of the French government. Since 2018, its objective has been to ensure the growth of the French Tech ecosystem and to witness its transformation into one of the most attractive and inclusive in the world. The French Tech mission contributes to this goal through special programs, funding, research, pro-startups public services and an impressive network of dozens of French Tech communities in France and around the world.

For more information: <https://lafrenchtech.com/>

Press contacts

Press relations

Najette Chaib

najettechaib@outlook.com

+33(0)6 18 38 11 14

EIT Health

Jérôme Fabiano

jerome.fabiano@eithealth.eu

+33(0) 6 42 25 73 41

LifeSci Advisors

Sophie Baumont

sophie@lifesciadvisors.com

+33(0) 6 27 74 74 49

HTFC

Nathalie Donne

nathalie.donne@insead.eu

+33(0)6 67 67 44 97

HTFC

Solène Goupy

solene.goupy@htfc-eu.com

+33(0)6 38 03 80 19

France Biotech

Florence Portejoie

FP2COM

fportejoie@fp2com.fr

+33(0)6 07 76 82 83